featured
Camrelizumab Plus Rivoceranib vs Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Lancet 2023 Jul 24;[EPub Ahead of Print], S Qin, SL Chan, S Gu, Y Bai, Z Ren, X Lin, Z Chen, W Jia, Y Jin, Y Guo, X Hu, Z Meng, J Liang, Y Cheng, J Xiong, H Ren, F Yang, W Li, Y Chen, Y Zeng, A Sultanbaev, M Pazgan-Simon, M Pisetska, D Melisi, D Ponomarenko, Y Osypchuk, I Sinielnikov, TS Yang, X Liang, C Chen, L Wang, AL Cheng, A Kaseb, A VogelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.